News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block
The 200 bedded hospital owned & operated by Alexis
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Subscribe To Our Newsletter & Stay Updated
